Vitamin D and primary hyperparathyroidism (PHPT).

Area of Science:

• Endocrinology
• Metabolic Bone Disease

Background:

• Vitamin D deficiency is prevalent in primary hyperparathyroidism (PHPT), particularly in postmenopausal women.
• Accelerated vitamin D metabolism in PHPT may exacerbate deficiency.
• Coexisting vitamin D deficiency can worsen PHPT phenotype, including larger tumors, higher PTH, and more severe bone disease.

Purpose of the Study:

• To investigate the safety and efficacy of vitamin D supplementation in PHPT patients.
• To explore the potential link between chronic vitamin D deficiency and tertiary hyperparathyroidism.
• To re-evaluate reference ranges for serum PTH by excluding individuals with vitamin D insufficiency.

Main Methods:

• Review of existing studies on vitamin D supplementation in PHPT.
• Analysis of potential mechanisms for vitamin D deficiency-induced tertiary hyperparathyroidism.
• Statistical analysis to determine revised PTH reference ranges excluding vitamin D insufficient subjects.

Main Results:

• Vitamin D supplementation is safe in PHPT patients with serum calcium <3 mmol/L, showing no increase in calcium levels and a decrease in PTH.
• Excluding individuals with vitamin D insufficiency from reference populations resulted in a 25-30% lower upper normal limit for serum PTH.
• A potential, though unclear, mechanism exists where long-term vitamin D deficiency might induce autonomous PTH secretion (tertiary hyperparathyroidism).

Conclusions:

• Vitamin D supplementation can be safely administered to PHPT patients with mild hypercalcemia.
• Vitamin D insufficiency significantly impacts serum PTH levels, necessitating its exclusion from normal reference populations.
• Revised PTH reference ranges accounting for vitamin D status are crucial for accurate diagnosis and management of hyperparathyroidism.